D. Mirchandani

520 total citations
15 papers, 379 citations indexed

About

D. Mirchandani is a scholar working on Oncology, Reproductive Medicine and Molecular Biology. According to data from OpenAlex, D. Mirchandani has authored 15 papers receiving a total of 379 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Oncology, 5 papers in Reproductive Medicine and 3 papers in Molecular Biology. Recurrent topics in D. Mirchandani's work include Ovarian cancer diagnosis and treatment (5 papers), Estrogen and related hormone effects (3 papers) and Endometrial and Cervical Cancer Treatments (3 papers). D. Mirchandani is often cited by papers focused on Ovarian cancer diagnosis and treatment (5 papers), Estrogen and related hormone effects (3 papers) and Endometrial and Cervical Cancer Treatments (3 papers). D. Mirchandani collaborates with scholars based in United States, Canada and Australia. D. Mirchandani's co-authors include Pradip Roy‐Burman, Jianping Zheng, Richard J. Côté, Darryl Shibata, Ananta K. Ghosh, Gary J. Miller, John Camoriano, Vera J. Suman, Daniel A. Nikcevich and Paul A. S. Fishkin and has published in prestigious journals such as Journal of Clinical Oncology, Clinical Cancer Research and Annals of Oncology.

In The Last Decade

D. Mirchandani

14 papers receiving 367 citations

Peers

D. Mirchandani

ONCOL

PRM

MB

CR

GENET

Uwe-Jochen Göhring Germany

P Vennin France

Ondřej Kubeček Czechia

Sumitra Ananda Australia

N Apostolikas Greece

Kyriaki Pliarchopoulou Greece

Elisabet Sanchez United Kingdom

Annette Bicher United States

Mancheng Gong China

Masaharu Ohgaki Japan

Uwe-Jochen Göhring Germany

D. Mirchandani

199 ×1.2

ONCOL

105 ×0.8

PRM

163 ×1.6

MB

74 ×0.8

CR

35 ×0.4

GENET

Citations per year, relative to D. Mirchandani D. Mirchandani (= 1×) peers Uwe-Jochen Göhring

Countries citing papers authored by D. Mirchandani

Since Specialization

Citations

This map shows the geographic impact of D. Mirchandani's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by D. Mirchandani with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites D. Mirchandani more than expected).

Fields of papers citing papers by D. Mirchandani

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by D. Mirchandani. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by D. Mirchandani. The network helps show where D. Mirchandani may publish in the future.

Co-authorship network of co-authors of D. Mirchandani

This figure shows the co-authorship network connecting the top 25 collaborators of D. Mirchandani. A scholar is included among the top collaborators of D. Mirchandani based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with D. Mirchandani. D. Mirchandani is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

15 of 15 papers shown

1.

Lange, Norbert, Janice S. Kwon, Ingrid Vandenput, et al.. (2019). Neoadjuvant Chemotherapy Followed by Surgery for Advanced-Stage Endometrial Cancer. Current Oncology. 26(2). 226–232. 33 indexed citations

2.

Hotte, Sébastien J., Elizabeth A. Eisenhauer, Anthony M. Joshua, et al.. (2013). NCIC CTG, IND-205: A phase II study of PX-866 in patients with recurrent or metastatic castration-resistant prostate cancer (CRPC).. Journal of Clinical Oncology. 31(15_suppl). 5042–5042. 6 indexed citations

3.

Mirchandani, D., Daniel F. Roses, Giorgio Inghirami, et al.. (2011). Loss of p27KIP1 expression in fully-staged node-negative breast cancer: association with lack of hormone receptors in T1a/b, but not T1c infiltrative ductal carcinoma.. PubMed. 31(12). 4401–5. 7 indexed citations

4.

Andreopoulou, Eleni, D. Mirchandani, A. Hamilton, et al.. (2007). Pegylated liposomal doxorubicin HCL (PLD; Caelyx/Doxil®): Experience with long-term maintenance in responding patients with recurrent epithelial ovarian cancer. Annals of Oncology. 18(4). 716–721. 58 indexed citations

5.

Ingle, James N., Vera J. Suman, Kendrith M. Rowland, et al.. (2006). Fulvestrant in Women With Advanced Breast Cancer After Progression on Prior Aromatase Inhibitor Therapy: North Central Cancer Treatment Group Trial N0032. Journal of Clinical Oncology. 24(7). 1052–1056. 101 indexed citations

6.

Yadav, Subhash, et al.. (2006). Gemcitabine-related thrombocytosis: Does it increase the risk of thrombosis?. Journal of Clinical Oncology. 24(18_suppl). 6091–6091. 2 indexed citations

7.

Wu, Jing, D. Mirchandani, Jayden A. Smith, et al.. (2006). Association of low P27 with loss of hormone receptors in small (T1a/b) breast cancers. Journal of Clinical Oncology. 24(18_suppl). 624–624. 1 indexed citations

8.

Mirchandani, D., Howard S. Höchster, Anne Hamilton, et al.. (2005). Phase I Study of Combined Pegylated Liposomal Doxorubicin with Protracted Daily Topotecan for Ovarian Cancer. Clinical Cancer Research. 11(16). 5912–5919. 24 indexed citations

9.

Muggia, Franco M., Kathleen McCaffrey, D. Mirchandani, et al.. (2004). Safety of prolonged Doxil administration in recurrent gynecologic cancers. Journal of Clinical Oncology. 22(14_suppl). 5055–5055. 1 indexed citations

10.

Haider, Kamal, Daygen L. Finch, Amer Sami, et al.. (2004). Largest series of extrapulmonary small cell carcinoma (ESCC): The Saskatchewan Experience. Journal of Clinical Oncology. 22(14_suppl). 9681–9681. 1 indexed citations

11.

Osborne, Raymond, et al.. (2004). Successful salvage of relapsed high-risk gestational trophoblastic neoplasia patients using a novel paclitaxel-containing doublet.. PubMed. 49(8). 655–61. 26 indexed citations

12.

Muggia, Franco M., Kathleen McCaffrey, D. Mirchandani, et al.. (2004). Safety of prolonged Doxil administration in recurrent gynecologic cancers. Journal of Clinical Oncology. 22(14_suppl). 5055–5055. 6 indexed citations

13.

Khandwala, Hasnain, et al.. (2004). Uncommon Presentations of Cancer Patients. Journal of Clinical Oncology. 22(23). 4851–4853. 5 indexed citations

14.

Haigentz, Missak, Mimi Kim, Joan Sorich, et al.. (2003). Phase I study of amifostine as a cytoprotector of the gemcitabine/cisplatin combination in patients with advanced solid malignancies. Anti-Cancer Drugs. 14(4). 321–326. 4 indexed citations

15.

Mirchandani, D., Jianping Zheng, Gary J. Miller, et al.. (1995). Heterogeneity in intratumor distribution of p53 mutations in human prostate cancer.. PubMed. 147(1). 92–101. 104 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact